Table 2.
EvRh | RSV | Influ | HPiV | hMPV | AdV | HCoV | HBoV | |
---|---|---|---|---|---|---|---|---|
Number of Episodes, n (%)a | 238 (40) | 136 (23) | 118 (20) | 97 (16) | 60 (10) | 12 (2) | 36 (6) | 17 (3) |
Overall IFD, n (%)a | 10 (4) | 7 (5) | 5 (4) | 5 (5) | 4 (7) | 1 (8) | 0 | 0 |
CARV URTD, n (%)a | 170 (72) | 79 (58) | 77 (65) | 61 (63) | 34 (57) | 4 (31) | 26 (72) | 12 (71) |
IFD after URTD, n (%)a | 2 (1) | 1 (1) | 0 | 0 | 1 (3) | 0 | 0 | 0 |
CARV LRTD, n (%)a | 68 (28) | 57 (42) | 41 (35) | 36 (37) | 26 (43) | 8 (66) | 10 (28) | 5 (29) |
IFD after LRTD, n (%)a | 8 (12) | 6 (11) | 5 (12) | 5 (14) | 3 (11) | 1 (13) | 0 | 0 |
Abbreviation: ADV, adenovirus; AdV, adenovirus; CARV, community‐acquired respiratory virus; EvRh, Enterovirus/rhinovirus; HCoV, human coronavirus; hMPV, human metapneumovirus; HPiV, human parainfluenza virus; IFD, invasive pulmonary fungal disease; Influ, human influenza virus; LRTD, lower respiratory tract disease; RSV, respiratory syncytial virus; URTD, upper respiratory tract disease.
The sum of the episodes does not match the overall number of episodes (n = 597) since multiple CARVs were detected in the same respiratory sample in 116 (19%) out of 597 CARV episodes. IFD after CARV co‐infection was 8% (9 out of 116)
This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.